CG-806 is an orally available, potent, and non-covalent pan-FLT3/pan-BTK inhibitor used for the treatment of acute myeloid leukemia (AML); it suppresses leukemia growth in vivo and induces apoptosis and cell cycle arrest in FLT3-mutant and wild-type AML cells, as well as inhibits BTK phosphorylation and malignant B-cell proliferation.